ATE244571T1 - Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor - Google Patents

Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor

Info

Publication number
ATE244571T1
ATE244571T1 AT93900793T AT93900793T ATE244571T1 AT E244571 T1 ATE244571 T1 AT E244571T1 AT 93900793 T AT93900793 T AT 93900793T AT 93900793 T AT93900793 T AT 93900793T AT E244571 T1 ATE244571 T1 AT E244571T1
Authority
AT
Austria
Prior art keywords
beta receptor
immunolobulin
inhibitory
polypeptides against
pdgf beta
Prior art date
Application number
AT93900793T
Other languages
English (en)
Inventor
Vanitha Ramakrishnan
Maria A Escobedo
Larry J Fretto
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE244571T1 publication Critical patent/ATE244571T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT93900793T 1991-12-02 1992-12-01 Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor ATE244571T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80179591A 1991-12-02 1991-12-02
PCT/US1992/010359 WO1993010805A1 (en) 1991-12-02 1992-12-01 Inhibitory immunoglobulin polypeptides to human pdgf beta receptor

Publications (1)

Publication Number Publication Date
ATE244571T1 true ATE244571T1 (de) 2003-07-15

Family

ID=25182043

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93900793T ATE244571T1 (de) 1991-12-02 1992-12-01 Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor

Country Status (10)

Country Link
EP (2) EP0619738B1 (de)
JP (3) JP3455743B2 (de)
AT (1) ATE244571T1 (de)
CA (1) CA2124958C (de)
DE (1) DE69233125T2 (de)
NZ (1) NZ246242A (de)
PL (1) PL171920B1 (de)
RU (1) RU2194760C2 (de)
SG (1) SG72635A1 (de)
WO (1) WO1993010805A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228600B1 (en) 1992-07-20 2001-05-08 The United States Of America As Represented By The Department Of Health And Human Services Immunoassays for the alpha platelet-derived growth factor receptor
US7252929B2 (en) 1989-02-09 2007-08-07 United States Of America, As Represented By The Secretary, Dept Of Health & Human Services Methods for identifying alpha PDGFR agonists and antagonists
ES2147729T3 (es) * 1991-01-31 2000-10-01 Cor Therapeutics Inc Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano.
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5620687A (en) * 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
DK0686044T3 (da) * 1993-02-25 2000-10-09 Zymogenetics Inc Hæmning af intimal hyperplasi under anvendelse af antistoffer mod PDGF-receptorer
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
CN101787073B (zh) * 2003-01-28 2013-12-25 艾恩伍德医药品股份有限公司 治疗胃肠病的方法和组合物
DE10337368A1 (de) * 2003-08-08 2005-03-03 Technische Universität Dresden Verfahren und Mittel zur Diagnose und Behandlung von Pankreastumoren
EP1756139A4 (de) 2004-03-12 2009-07-29 Entremed Inc Antiangiogene mittel
WO2007109312A2 (en) 2006-03-20 2007-09-27 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
EP2155238B1 (de) 2007-06-05 2016-04-06 Yale University Antikörper gegen die d4 domäne des kit rezeptors und anwendungsverfahren
BRPI0916973A2 (pt) 2008-08-18 2016-07-26 Amgen Fremont Inc anticorpos para ccr2
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
TWI640537B (zh) 2011-12-05 2018-11-11 Ｘ 染色體有限公司 ＰＤＧＦ受體β結合多肽
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339356C (en) * 1988-02-02 1997-08-26 Lewis T. Williams Human platelet-derived growth factor receptor
EP0456766B1 (de) * 1989-02-09 1999-04-28 The United States Of America Zuwachsfaktorrezeptorgen deriviert von platten des typs oc

Also Published As

Publication number Publication date
RU2194760C2 (ru) 2002-12-20
PL171920B1 (pl) 1997-06-30
EP1350799A3 (de) 2003-12-03
EP1350799A2 (de) 2003-10-08
JP2000355548A (ja) 2000-12-26
JPH07501806A (ja) 1995-02-23
AU3232893A (en) 1993-06-28
CA2124958A1 (en) 1993-06-10
DE69233125D1 (de) 2003-08-14
JP3455743B2 (ja) 2003-10-14
EP0619738A4 (en) 1996-07-03
JP2000355600A (ja) 2000-12-26
RU94031472A (ru) 1996-04-20
WO1993010805A1 (en) 1993-06-10
DE69233125T2 (de) 2004-04-22
NZ246242A (en) 1996-01-26
SG72635A1 (en) 2000-05-23
CA2124958C (en) 2007-02-13
AU672377B2 (en) 1996-10-03
EP0619738B1 (de) 2003-07-09
EP0619738A1 (de) 1994-10-19
JP3732385B2 (ja) 2006-01-05

Similar Documents

Publication Publication Date Title
ATE244571T1 (de) Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor
PT848755E (pt) Proteina relacionada com o vegf
NO991162D0 (no) Monoklonale antistoffer mot det ekstracellulµre domene av humant VEGF-reseptorprotein (KDR)
DK0643608T3 (da) Proteinrensning
ATE386116T1 (de) Bindungsdomänen des serrate-proteins
NO980915D0 (no) Rekombinante anti-CD4-antistoff egnet for human terapi
DE69638269D1 (de) Hochaffine humane antikörper gegen tumorantigene
ATE255906T1 (de) Antikörper gegen cd40
DE69617896D1 (de) Humaner monoklonaler Antikörper gegen VEGF
ATE234922T1 (de) Il-13 rezeptor polypeptid
LV11630A (lv) T sunu antigena receptora V apgabala pilna garuma olbaltumvielas
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
DE69322847D1 (de) Monoklonaler Antikörper gegen menschliches Ceruloplasmin
FI20095269A (fi) Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli
DE3687542D1 (de) Monoklonaler antikoerper gegen humanes protein c.
DE69333683D1 (de) Antikörper-testbesteck zur bestimmung von amylin
DE69020315D1 (de) Monoklonaler antikörper gegen c-reaktives protein.
ITRM920223A0 (it) Anticorpi monoclonali anti-idiopici diretti contro anticorpi anti-tnf.
RU94007095A (ru) Химеровые человеческие интерферон-гамма-рецептор/иммуноглобулин полипептиды
GB2333295A (en) Modified protein G and fragments thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0619738

Country of ref document: EP